|50.77|| -0.29 / -0.57%|
Abbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products. The company operates through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes branded generic pharmaceuticals manufactured, marketed and sold outside the United States and are generally sold directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its owned distribution centers and public warehouses, depending on the market served. The Diagnostic Products segment includes diagnostic systems and tests manufactured, marketed, and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, government agencies, alternate-care testing sites, and plasma protein therapeutic companies. The segment's products are generally marketed and sold directly from Abbott-owned distribution centers, public warehouses and third-party distributors. The Nutritional Products segment includes pediatric and adult nutritional products manufactured, marketed, and sold worldwide. Its products are generally marketed and sold directly to customers and to institutions, wholesalers, retailers, health care facilities, government agencies, and third-party distributors from owned distribution centers or third-party distributors. The Vascular Products segment includes coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease manufactured, marketed and sold worldwide. The segment's products are generally marketed and sold directly to hospitals from Abbott-owned distribution centers and public warehouses. Abbott Laboratories was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
|Miles D. White||Chairman & Chief Executive Officer|
|Brian B. Yoor||Chief Financial Officer & VP-Investor Relations|
|Preston T. Simons||Vice President-Information Technology|
|Kathryn S. Collins||Vice President, Chief Ethics & Compliance Officer|
|Hubert L. Allen||Secretary, Executive VP & General Counsel|